In a recent The Medicine Maker article, Austin Px CEO Elizabeth Hickman and CSO Dave Miller discuss how KinetiSol is opening new possibilities beyond oral delivery, including injectable therapies and dry powder inhalation, as researchers look for better ways to work with poorly soluble compounds. They also say the growing complexity of small molecule development is raising expectations for CDMOs, which are expected to pair technical depth with delivery expertise to help emerging drug developers move promising molecules closer to the clinic and, ultimately, to patients.
